依普利酮怎么服用？

Generic drugs are produced by Lupine Pharmaceuticals in India. Eplerenone is approved to treat high blood pressure. The advantages of eplerenone include: 1. For the treatment of heart failure after acute myocardial infarction, combined with standard treatment drugs, the total mortality rate in the treatment group can be reduced by 15%; 2. Eplerenone is equally effective as enalapril in reversing left ventricular hypertrophy and hypertension, with fewer cough side effects, and the combined effect is more obvious; 3. Few adverse reactions, except for the adverse reactions of increased blood potassium, other adverse reactions are no different from the placebo group; 4. There are almost no sex hormone-related side effects of spironolactone.

How to take eplerenone from Lupine Pharmaceuticals in India?

1. For congestive heart failure after acute myocardial infarction: The recommended dose of eplerenone from India's Lupine Pharmaceuticals is 50 mg/time, once/day. The initial dose should be 25 mg/time, once/day, and within 4 weeks, the dose should be gradually increased to 50 mg/time, once/day under the conditions tolerated by the patient within 4 weeks.

2. Anti-hypertension: India's Lupine Pharmaceuticals eplerenone can be used alone or in combination with other anti-hypertensive drugs. The recommended initial dose for use alone is 50mg/time, once/day. Obvious antihypertensive effects appear within four weeks of taking the drug. If the antihypertensive effect is not obvious, it can be increased to 50mg/time, 2 times/day. Higher dosages are not recommended, otherwise there is an increased risk of adverse reactions such as hyperkalemia.

Medical companions remind patients: Indian Lupine Pharmaceuticals cannot be combined with potassium supplements, potassium-containing salts or contraindicated drugs (potassium-sparing diuretics, strong inhibitors of CYP450 liver enzymes). Eplerenone non-steroidal anti-inflammatory drugs and lithium can affect the blood concentration of this product and affect its efficacy.

Recommended related hot articles: /newsDetail/86626.html